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Abstract
Background: Children with longstanding use of antiepileptic drugs (AEDs) are susceptible to developing low bone
mineral density and an increased fracture risk. However, the literature regarding the effects of AEDs on growth in
epileptic children is limited. The aim of this study was to investigate the potential effects of valproate (VPA) and/or
oxcarbazepine (OXC) therapy on growth velocity and bone metabolism.
Methods: Seventy-three ambulatory children (40 boys and 33 girls) with epilepsy, aged between 1 and 18 years
(mean age 9.8 ± 4.1 years), were evaluated for growth velocity before and for 1 year after VPA and/or OXC
treatment. The bone resorption marker serum tartrate-resistant acid phosphatase 5b (TRAcP5b) and the bone
formation marker serum bone-specific alkaline phosphatase (BAP) were measured post-AEDs therapy for 1 year.
Results: The difference in growth velocity (ΔHt) and body weight change (ΔWt) between pre- and post-AEDs
treatment were -1.0 ± 2.8 cm/year (P < 0.05) and 0.1 ± 3.9 kg/year (P = 0.84), respectively. The study population had
serum TRAcP5b-SDS of -1.6 ± 1.2 and BAP-SDS of 1.7 ± 3.7 compared with sex- and age-matched healthy children.
Significant correlation between serum TRAcP 5b and BAP activities was noted (r = 0.60, p < 0.001). There was a
positive correlation between growth velocity and serum TRAcP 5b activity after AED treatment (r = 0.42, p < 0.01).
No correlation was found between ΔHt, ΔWt, serum TRAcP 5b, BAP activity and types of AEDs.
Conclusion: Growth velocity was significantly decreased in epileptic children after 1 year of VPA and/or OXC
treatment. The effect of VPA and/or OXC therapy on dysregulation of bone metabolism might play a crucial role in
physical growth.
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Background
Antiepileptic drugs (AEDs) have been shown to be associ-
ated with a lowering of bone mineral density (BMD) in
childhood and adolescence [1–3], which are critical pe-
riods for bone mineralization [4]. The underlying patho-
physiological mechanisms of AEDs on bone metabolism
are poorly understood but are probably multifactorial, and
include inducing cytochrome p450 enzyme activities [5],
increased bone turnover [6], inhibition of osteocalcin [7],
and increased urinary loss of calcium and phosphorus.
Along with decreased BMD, the disturbance of phys-
ical growth during AEDs treatment is also of great con-
cern to physicians. It has been reported that long-term
valproate (VPA) and lamotrigine (LTG) therapy, particu-
larly when combined, is associated with short stature [8].
However, the alteration in growth is postulated to be
mediated through immobility, not by the AEDs therapy
* Correspondence: pedneuchen@hotmail.com
1Department of Pediatrics, Tri-Service General Hospital, National Defense
Medical Center, No.325, Cheng-Kung Road, Section 2, Nei-Hu, Taipei 114,
Taiwan
Full list of author information is available at the end of the article
© 2016 Lin et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Lin et al. BMC Pediatrics  (2016) 16:61 
DOI 10.1186/s12887-016-0597-7
itself [8]. In addition to the investigations into static
height only [8], Rattya J et al. conducted a longitudinal
growth analysis to evaluate the effect of VPA, carba-
mazepine (CBZ), or oxcarbazepine (OXC) therapy on
physical growth [9]. Of note, AEDs treatment did not
affect linear growth in girls with epilepsy [9]. Taken to-
gether, findings regarding the adverse effects of AEDs
therapy on growth stature are still inconsistent [8, 9].
Furthermore, the literature regarding the influence of
AEDs on dynamic height (growth velocity) in epileptic
children is limited, and the effects of AEDs on growth
via disregulation of bone mineralization are not fully
known. Therefore, we conducted a cross-sectional co-
hort study to evaluate growth velocity and bone turn-
over markers in growing Taiwanese children with
epilepsy to identify the potential effects of VPA and
OXC therapy on decreased growth velocity and disrup-
tion of bone metabolism.
Methods
Participants and study design
Seventy-three ambulatory outpatients with epilepsy aged
1 to 18 years who visited the Department of Pediatrics
of Tri-Service General Hospital in Taiwan were enrolled.
Based on the International League Against Epilepsy clas-
sification [10], all patients were definitively diagnosed
with epilepsy or epileptic syndrome and were taking
VPA (n = 23), OXC (n = 29), or VPA combined with
OXC (n = 21). All of them were free of seizure for longer
than 6 months after AEDs treatment and had an active
daily life. Exclusion criteria were acute or chronic dis-
ease affecting bone metabolism, significant disabilities
such as mental or motor retardation, endocrinologic dis-
eases, taking medications other than AEDs, or any other
comorbidity, such as muscular dystrophy, neurological
conditions, or recent osteomyelitis. Legal guardians or
parents of subjects aged less than 7 years signed an in-
formed consent. Both subjects and their legal guardians
or parents had to sign a combination assent/parental
permission form written simply and at a comprehensive
level appropriate for children between ages 7 to 18.
The Ethics Review Committee of Tri-Service General
Hospital approved this study.
Anthropometry
Because growth velocity varies at different stages of life,
participants were classified into three subgroups accord-
ing to pubertal age: pre-puberty (boy 1–8 years, girl 1–
7 years), puberty (boy 9–14 years, girl 8–13 years), and
post-puberty (boy 15–18 years, girl 14–18 years). Retro-
spective growth data were gathered only from the re-
cords at Tri-Service General Hospital, with an accuracy
of 0.5 cm for height and 0.1 kg for weight. Height was
measured to the nearest 1.0 mm with the same
Harpenden wall-mounted stadiometer and weight to the
nearest 0.1 kg on a calibrated weight scale at the clinical
examination. The difference in growth velocity and body
weight change before and for 1 year after AEDs treat-
ment was expressed as ΔHt and ΔWt, respectively.
Blood sampling
Upon entry, a blood sample was drawn at 8:00 AM
after an overnight fast for the evaluation of plasma as-
partate aminotransferase (AST), alanine aminotransfer-
ase (ALT), blood urea nitrogen (BUN), creatinine (Cre),
alkaline phosphatase (ALP), total calcium (Ca), free Ca,
phosphorus (P), and blood hemoglobin (Hgb). Another
blood sample was taken for two bone turnover markers,
the serum bone resorption marker TRAcP 5b [11, 12]
and the bone formation marker BAP activities, after
AEDs therapy for 12 months. Serum TRAcP 5b was
assessed by a solid phase, immunofixed, enzyme activity
assay as described previously [13] with an intra- and
inter-assay CV of 5.1 % and 3.9 %, respectively. BAP ac-
tivity was measured using a commercially available
quantitative ELISA kit (Metra BAP EIA kit, Quidel
Corp., San Diego, CA) in which serum BAP was immo-
bilized by a specific antibody and its activity measured
using 4-nitrophenyl phosphate as the substrate.
Statistical analyses
Basic data were calculated as mean values with standard
deviation. Anthropometry data, serum TRAcP 5b and
BAP activities were compared with age- and sex-
specific Taiwanese reference values and presented as
standard deviation scores (SDS = [x-mean]/SD) [14, 15].
The statistical analysis was performed by means of the
Student’s t test (two-tailed) and one-way analysis of
variance (ANOVA) for comparison of continuous vari-
ables. Pearson’s correlation analysis was used to esti-
mate the relationships between serum TRAcP 5b, BAP
activities, and growth velocity after AEDs treatment. A
p-value < 0.05 was considered significant.
Results
Basic demographic and biochemical data of epileptic
children at baseline and 1 year post-AEDs treatment
are shown in Table 1. The 73 patients (40 boys and 33
girls) had a mean age (± SD) of 9.8 ± 4.1 years, height-
SDS of -0.2 ± 1.3, weight-SDS of 0.5 ± 1.8, and body
mass index-SDS of 1.1 ± 2.6 [14]. The baseline serum
levels of AST/ALT, BUN/Cre, ALP, total Ca, free Ca, P
and blood Hgb were all within normal ranges. The
mean TRAcP 5b activity was 4.8 ± 1.7 μmol/L/min and
the mean BAP activity was 144.4 ± 73.2 μmol/L/min
after AEDs treatment for 1 year. Compared with the sex-
and age-matched healthy Taiwanese children, TRAcP5b-
SDS was -1.6 ± 1.2 and BAP-SDS was 1.7 ± 3.7 [15].
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Growth velocity post-AEDs treatment had a de-
creasing trend in all three subgroups (ΔHt: pre-
puberty -1.4 ± 3.3 cm/year; puberty -0.7 ± 2.6 cm/year;
post-puberty -0.7 ± 1.8 cm/year) (Table 2). Overall, the
difference in growth velocity between pre- and post-
AEDs treatment was -1.0 ± 2.8 cm/year (P < 0.05). The
differences in body weight change between pre- and
post-AEDs treatment were 1.2 ± 3.0 kg/year in pre-puberty
and -3.3 ± 6.6 kg/year in post-puberty, respectively. Among
all participants, there was no significant difference in
body weight change between pre- and post-AEDs treat-
ment (P = 0.84).
There was a significant correlation between serum
TRAcP 5b and BAP activity after AED treatment (r =
0.60, p < 0.001) (data not shown). In Table 3, a positive
correlation between growth velocity after AEDs treat-
ment and serum TRAcP 5b activity was noted in the
post-pubertal group (r = 0.93, p < 0.01) and in all patients
(r = 0.42, p < 0.01). No correlation was found between
ΔHt, ΔWt, serum TRAcP 5b, BAP activity and types of
AEDs (data not shown).
Discussion
Our findings of a decrease in the bone resorption
marker TRAcP 5b-SDS (-1.6 ± 1.2), an increase in the
bone formation marker BAP-SDS (1.7 ± 3.7), and a sig-
nificant correlation between serum TRAcP 5b and BAP
activities (r = 0.60, p < 0.001) might be indirect evidence
of increased bone turnover. In terms of body height, a
decreased growth velocity after VPA and/or OXC ther-
apy for 1 year (-1.0 ± 2.8 cm/year, p < 0.05) and a signifi-
cantly positive correlation between growth velocity and
serum TRAcP 5b activity after AEDs therapy (r = 0.42,
p < 0.01) were observed in all subjects. These interest-
ing findings might partly explain the crucial role of the
uncoupling of bone metabolism in decelerated physical
growth in growing children with short-term VPA and/
or OXC treatment. To our knowledge, the present
study is the first report to delineate the relationship be-
tween decreased growth velocity and the short-term
use of VPA and/or OXC therapy in a representative
Taiwan population-based sample. However, a well-
controlled longitudinal study with more patients and
Table 1 Demographic and biochemical data of epileptic





Age (yrs) 9.8 ± 4.1
Type of AEDs (N)
Valproate 23
Oxcarbazepine 29
Valproate + Oxcarbazepine 21
Growth evaluation
Height (cm) 133.5 ± 21.5
Height-SDS -0.2 ± 1.3
Weight (kg) 35.0 ± 17.0
Weight-SDS 0.5 ± 1.8
Body mass index-SDS 1.1 ± 2.6
Laboratory studies
Aspartate aminotransferase (U/L) 27.6 ± 7.5
Alanine aminotransferase(U/L) 17.1 ± 7.8
Blood urea nitrogen (mg/dL) 13.0 ± 1.2
Creatinine (mg/dL) 0.5 ± 0.2
Alkaline phosphatase (U/L) 226.8 ± 85.0
Total calcium (mg/dL) 9.5 ± 0.4
Free calcium (mg/dL) 4.9 ± 0.3
Phosphorous (mg/dL) 4.7 ± 0.3
Hemoglobin (g/dL) 13.0 ± 1.2
Post-treatment
Laboratory studies
Serum TRAcP5b (umol/L/min) 4.8 ± 1.7
TRAcP5b-SDS -1.6 ± 1.2
Serum BAP (umol/L/min) 144.4 ± 73.2
BAP-SDS 1.7 ± 3.7
Total calcium (mg/dL) 9.2 ± 0.3
Free calcium (mg/dL) 4.7 ± 0.3
aData presented as mean ± SD
Table 2 Growth velocity and body weight change of epileptic children before and after AEDs treatment
Patients No. Growth velocity (cm/yr) Body weight change (kg/yr)
M/F Total Pre-AEDs Post-AEDs ΔHta p-value* Pre-AEDs Post-AEDs ΔWtb p-value*
Pre-puberty 19/9 28 6.7 ± 3.4 5.3 ± 1.3 -1.4 ± 3.3 0.13 1.9 ± 1.8 2.7 ± 2.0 1.2 ± 3.0 0.33
Puberty 13/17 30 6.5 ± 3.4 5.8 ± 2.0 -0.7 ± 2.6 0.30 3.9 ± 2.8 4.7 ± 2.7 0.5 ± 3.0 0.29
Post-puberty 8/7 15 3.7 ± 2.8 3.0 ± 1.9 -0.7 ± 1.8 0.35 4.3 ± 7.4 1.0 ± 2.3 -3.3 ± 6.6 0.27
Overall 40/33 73 6.1 ± 3.4 5.2 ± 2.0 -1.0 ± 2.8 0.04 3.2 ± 3.6 3.4 ± 2.7 0.1 ± 3.9 0.84
Data presented as mean ± SD; aThe difference in growth velocity between pre- and post-AEDs treatment; bThe difference in body weight change between pre-
and post-AEDs treatment; *P-value between pre- and post-AEDs treatment
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evaluation of more bone turnover markers is needed to
confirm our hypothesis.
Both enzyme-inducing and non-enzyme inducing AEDs
can cause abnormalities in bone metabolism [16–19]. The
negative influence of AEDs on BMD is complex and not
understood completely, but several lines of evidence sug-
gest a role for the induction of cytochrome p450 enzyme
activities, which accelerate vitamin D hydroxylation to in-
active forms [5], increased bone turnover [6], inhibition of
osteocalcin [7], and decreased intestinal transport of cal-
cium [20]. Besides decreased BMD, the influence of AEDs
treatment on physical growth is of great concern in clin-
ical practice nowadays. However, the literature regarding
the adverse effect of AEDs therapy on growth stature is
very limited and the results are inconsistent [8, 9]. Guo et
al. reported long-term VPA and LTG therapy, particularly
when combined, is associated with short stature, low
BMD, and reduced bone formation; but these alterations
are thought to be mediated primarily through reduced
physical activity rather than though a direct link to AEDs
therapy [8]. In contrast to the investigation of static height
alone [8], our study found epileptic children with normal
daily activity had decreased dynamic growth patterns as-
sociated with increased bone turnover after short-term
VPA and/or OXC treatment. Although Rattya et al. re-
ported VPA, CBZ, or OXC seem not to have an adverse
effect on linear growth in girls with epilepsy, VPA-related
weight gain could be observed in that series [9]. As illus-
trated, weight gain induced advanced bone age resulting
in rapid growth may partially mask the true effect of VAP
on growth in that series. On the contrary, our three study
subgroups all had a trend toward a decrease in growth
velocity, no matter whether body weight increased or
not. There was a lack of obvious weight gain in our
study, which is typically associated with a protective ef-
fect on bone mineralization [21], so we supposed that
the decelerated growth velocity might not be attributed
to body weight change, but to AEDs treatment itself.
Nevertheless, the effect of the interaction between
AEDs therapy and genetic, hormonal, and environmen-
tal factors on physical growth in Taiwanese epileptic
children still should be considered.
In adults and children, VPA therapy is associated with
weight gain, high body fat, and hyperleptinaemia [9, 22].
Thus, it is speculated that VPA could affect bone mass
accrual and/or turnover indirectly through weight gain
and the associated hyperleptinaemia [19]. However, the
AEDs-induced weight gain was only observed in patients
taking VPA, not in those treated with OXC [9]. In con-
trast to previous reports [9, 22], the differences in body
weight change between pre- and post-VPA and/or OXC
treatment did not alter significantly in the present study
(p = 0.84). Furthermore, our study found no correlation
between ΔWt and usage of types of AEDs (data not
shown). We supposed that the effect of VPA on weight
gain in all participants might be masked by decreased
body weight gain in the post-pubertal subgroup, in con-
sideration of the elevated self-image and sense of self-
esteem, as well as the lack of body weight change with
OXC therapy [9]. Of importance, the weight gain in pa-
tients treated with VPA was slow but progressive [9],
which may subsequently increase weight-bearing for
bone remodeling, BMD, and linear growth. Therefore,
the possibility of weight gain in epileptic patients should
be monitored during long-term VPA treatment to eluci-
date its true effect on bone growth.
Serum vitamin D levels were not measured in our
study. Vitamin D deficiency in participants with epilepsy
was reported to be common in some, but not all, earlier
studies [19, 23–25]. These discrepant results may be at-
tributed to whether AEDs, with their cytochrome P450
enzyme inducers, which increase vitamin D metabolism,
were used or not. On the other hand, confounding fac-
tors such as AEDs polytherapy and immobility may also
contribute to vitamin D deficiency/insufficiency in epi-
leptic patients [8, 26]. In contrast to strong enzyme in-
ducers such as CBZ, non-enzyme-inducing (VPA) and
minimal enzyme-inducing (OXC) agents were used by
our participants. All subjects in the present study were
ambulatory and normally physically active. Furthermore,
Taiwan is a subtropical Asian country and so sunlight
exposure was also adequate. Herein, disruption to bone
metabolism related to vitamin D deficiency seemed not
to be an important contributor to decreased growth vel-
ocity in our series.
Nevertheless, our study has some limitations. Firstly,
there was a lack of X-ray image to investigate the rela-
tionship between BMD, bone age study and growth vel-
ocity. However, due to the fear of high-level exposure to
radiation, the risk-benefit analysis did not justify per-
forming BMD measurements in present study, particu-
larly from a parental point of view. Furthermore,
findings regarding the effect of AEDs on BMD are still
conflicting [23, 24, 26–28]. Secondly, the functions of in-
sulin like growth factor-I (IGF-I) were potentially to in-
crease markers of osteoblastic activity and reduce bone
resorption [29]; and serum IGF-binding proteins-2
(IGFBP-2) levels was associated with low BMD and high
bone resorption markers [30, 31]. However, the growth
Table 3 Correlation of coefficient between growth velocity after
AEDs treatment and bone turnover markers
Growth velocity after AEDs treatment
Pre-puberty Puberty Post-puberty Overall
Serum TRAcP5b 0.07 0.23 0.93* 0.42*
Serum BAP 0.04 0.01 0.49 0.22
*P < 0.01
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hormone (GH)/IGF axis, which is essential to maintain
homeostasis of bone turnover, was not evaluated in our
study [32]. Finally, our patient sample size was small and
was not equally distributed across age subgroups, which
might explain why the differences in growth velocity be-
tween pre- and post-AEDs treatment were significant
overall, but not in each subgroup. Therefore, a larger-
scale prospective study in consideration of IGF-I,
IGFBP-2, bone turnover biomarkers, and growth velocity
is necessary to clarify our hypothesis of AEDs on growth
and bone metabolism.
Conclusion
Our findings suggest that 1-year survey of VPA and/or
OXC therapy among growing epileptic children might
be associated with decreased growth velocity. This alter-
ation seems to be mediated through the effect of AEDs
on dysregulation of bone metabolism. To monitor growth
velocity and bone metabolism, a larger-scale, long-term
prospective study considering weight gain effect of AEDs,
genetic, hormonal, and nutritional factors is needed to elu-
cidate the true effects of AEDs itself on physical growth.
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